Wealthfront Advisers LLC purchased a new position in Integer Holdings Co. (NYSE:ITGR - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 35,873 shares of the medical equipment provider's stock, valued at approximately $4,754,000. Wealthfront Advisers LLC owned approximately 0.11% of Integer at the end of the most recent reporting period.
A number of other hedge funds also recently modified their holdings of the business. Mather Group LLC. increased its stake in Integer by 304.3% during the 4th quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 143 shares in the last quarter. Huntington National Bank boosted its holdings in shares of Integer by 8,933.3% in the third quarter. Huntington National Bank now owns 271 shares of the medical equipment provider's stock valued at $35,000 after buying an additional 268 shares during the period. R Squared Ltd bought a new stake in shares of Integer during the fourth quarter worth $44,000. Versant Capital Management Inc raised its holdings in shares of Integer by 98.4% during the fourth quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider's stock worth $49,000 after acquiring an additional 183 shares during the period. Finally, Principal Securities Inc. lifted its position in Integer by 31.2% in the 4th quarter. Principal Securities Inc. now owns 639 shares of the medical equipment provider's stock valued at $85,000 after acquiring an additional 152 shares in the last quarter. Institutional investors and hedge funds own 99.29% of the company's stock.
Integer Trading Down 1.0 %
Shares of Integer stock opened at $118.41 on Friday. The stock has a market cap of $3.98 billion, a P/E ratio of 35.24, a P/E/G ratio of 1.72 and a beta of 1.24. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62. Integer Holdings Co. has a 12-month low of $107.11 and a 12-month high of $146.36. The business's 50 day moving average is $134.43 and its 200-day moving average is $132.75.
Integer (NYSE:ITGR - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.46 by ($0.03). Integer had a return on equity of 11.65% and a net margin of 6.92%. The firm had revenue of $449.50 million for the quarter, compared to the consensus estimate of $446.28 million. Equities research analysts predict that Integer Holdings Co. will post 6.01 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities analysts have issued reports on ITGR shares. Citigroup increased their target price on Integer from $130.00 to $145.00 and gave the stock a "neutral" rating in a report on Wednesday, December 11th. KeyCorp increased their price objective on Integer from $144.00 to $154.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Oppenheimer cut Integer from an "outperform" rating to a "market perform" rating in a research note on Friday, February 21st. Truist Financial raised their price target on shares of Integer from $147.00 to $163.00 and gave the stock a "buy" rating in a research note on Wednesday, December 11th. Finally, Wells Fargo & Company reiterated an "overweight" rating and issued a $160.00 price objective on shares of Integer in a report on Tuesday, December 3rd. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Integer currently has an average rating of "Moderate Buy" and a consensus target price of $147.67.
View Our Latest Report on ITGR
Integer Profile
(
Free Report)
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Integer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integer wasn't on the list.
While Integer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
